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Abstract 
 
Cigarette smoking in those who are alcohol dependent is associated with higher morbidity 
and mortality. The A1 allele of the D2 dopamine receptor (DRD2) gene has been 
independently associated with alcohol and nicotine dependence. Whether this polymorphism 
is associated with nicotine dependence in those who are also alcohol dependent has not been 
investigated. Subjects were 84 (61 males; 23 females) Caucasian DSM IV diagnosed 
nicotine-and alcohol-dependent subjects sampled from consecutive admissions to a hospital 
alcohol detoxification ward. Data were obtained through standardised measures of nicotine 
and alcohol consumption and dependence severity. A1+ allelic (A1/A1 or A1/A2 genotype) 
compared to A1- allelic (A2/A2 genotype only) patients were characterised by higher levels 
of alcohol and cigarette consumption. A1+ allelic patients reported greater alcohol 
dependence severity, but not nicotine dependence severity. When the combined nicotine and 
alcohol dose was examined, A1+ allelic patients consumed significantly more of these drugs 
than their A1- allelic counterparts.  
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1. Introduction 
The World Health Organization has listed tobacco and alcohol misuse as being among the 
five most significant risk factors associated with the global burden of disease (Powles & 
Day, 2002). Tobacco smoking will become the leading global disease burden by 2020 
(Murray & Lopez, 1996). There is a significant association between alcohol and tobacco 
misuse (Bein & Burge, 1990), with high levels (>80%) of comorbid dependence 
(Pomerleau, Aubin & Pomerleau, 1997). While, the morbidity and mortality attributed to 
these substances alone is considerable, the combined effects of cigarette smoking and 
heavy alcohol consumption represent an even higher disease risk. Recent meta-analyses 
show that concurrent tobacco and alcohol misuse significantly increase the risk for upper 
digestive tract (Bagnardi, Blangairdo, La Vecchia & Corrao, 2001) and respiratory tract 
(Korte, Brennan, Henley & Boffetta, 2002) carcinoma. Up to one-third of oral cavity 
cancer risk has been attributed to the combination of cigarette smoking and alcohol 
consumption amongst males (Balaram et al., 2002). Furthermore, there is a combined 
influence of cigarettes and alcohol on respiratory disease. Alcohol consumption itself is a 
significant risk factor associated with lung capacity decline (Burchfiel et al., 1996; Ström 
et al., 1996). A large scale German epidemiological study of over seven million hospital 
admissions found that 32.2% of the total in-patient treatment costs were associated with 
tobacco- or alcohol-attributed disease (John, Rumpf, Hanke, Gerke & Hapke, 2003). 
 
The negative impact of cigarette smoking on health in those with an alcohol problem is 
illustrated by retrospective data examining the cause of death of 845 alcohol-dependent 
individuals (Hurt et al., 1996). These data showed that amongst those with alcohol 
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dependence, the effects of alcohol were responsible for one-third of deaths, whereas 
smoking accounted for more than half of the deaths. In terms of psychosocial morbidity, the 
quality of life and mental health of those with alcohol problems (Connor, Saunders & 
Feeney, 2006; Foster, Powell, Marshall & Peters, 1999) and smokers (Olufade et al., 1999) 
is rated poorly.  
 
The development of comorbid nicotine and alcohol dependence is influenced by a complex 
interplay of genetic and environmental factors. Twin studies have demonstrated the 
heritability component of alcohol (Pickins et al., 1991; Prescott, Aggen & Kendler,1999) 
and nicotine (True et al., 1997) misuse to be in the order of 60%. It is likely that much of 
this genetic variance is shared (Koopmans, van Dooren & Boomsma, 2002). Association 
studies which compare the frequency of candidate genes between drug-dependent and non-
drug-dependent groups have proposed a range of potential genetic markers for alcohol and 
nicotine dependence (Fergusson & Goldberg, 1997). One such marker, the D2 dopamine 
receptor (DRD2) gene, has shown considerable promise across independent association 
studies of substance dependence, including alcohol and nicotine. For example, in an analysis 
of the Collaborative Study on the Genetics of Alcoholism (COGA) data, an independent 
research group found that only two regions, one containing the candidate gene ADH3, the 
other the DRD2, were implicated in alcohol dependence (Waldman, Robinson & Rhee, 
1999). While the majority of association study meta-analyses have consistently found a 
higher prevalence of the DRD2 A1 allele in individuals with alcohol misuse disorders 
compared to controls (Cloninger, 1991; Gorwood, Ades & Feingold, 1994; Gurling & Cook, 
1999; Lawford et al., 1997; Noble, 2003; Pato, Macciareli, Pato, Verga & Kennedy, 1994; 
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Young et al, 2004) one meta-analysis (Gelernter, Goldman & Risch,1993) has not (see 
Noble & Blum, 1993). The increasing frequency of A1+ allelic status (A1/A1 and A1/A2 
genotypes) is associated with increasing severity of alcohol dependence (Lawford et al., 
1997; Noble, 2003). This is evident in multiple ethnic or racial groups suggesting that the 
association described is not simply due to population stratification (Young et al, 2004).  
 
A recent meta analysis of candidate genes potentially related to smoking confirmed the 
association between the A1 allele of the DRD2 and smoking initiation as well as response to 
treatment (Munafo et al., 2004). A1+ allelic status is more likely found in smokers than non-
smokers (Noble et al., 1994; Comings et al., 1996; Pastorelli et al., 2001), although 
Singleton et al., (1998), using a combined community and post-mortem sample, found no 
association between the DRD2 A1 allele and smoking status. However, a meta-analysis of 9 
different studies of 1,721 smokers and 2,119 non-smokers (Noble, 2003) found the 
prevalence of the A1 allele to be significantly higher in smokers than those who do not 
smoke (p = 1.29 x 10-7). The A1 allele is also associated with number of cigarettes smoked 
(Waldman, et al., 1999) and the familial aggregation of smoking-related cancers (Wu, 
Hundmon, Detry, Chamberlaine & Spitz, 2000). Further, DRD2 A1- (A2/A2 genotype only) 
allelic status is also associated with a greater likelihood of never having smoked (Anokhin, 
Todorov, Madden, Grant & Heath, 1999; Lerman et al., 1999). Moreover, the A1+ (A1A1 
or A1A2 genotype) allelic status is more common amongst polysubstance misusers (Smith, 
et. al., 1992), although the subgroup of heavy drinkers and cigarette smokers were not 
examined separately. 
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In sum, the DRD2 A1 allele is individually associated with severe alcohol and nicotine 
misuse problems. Whether this polymorphism is associated with nicotine misuse in those 
who are also alcohol dependent has not been investigated. This study aims to explore this 
relationship by examining DRD2 allelic status and key drinking and smoking indices 
within an alcohol-dependent population. 
 
 
2. Methods 
 
2.1 Participants 
Subjects in this study were 84 Caucasian inpatient smokers (61 males; 23 females) sampled 
from consecutive admissions to a hospital alcohol detoxification ward. These smokers were 
recruited from a larger study investigation alcohol treatment issues (Connor et al., 2002). 
 
Subjects were recruited from days 2-5 of their detoxification. All patients (a) satisfied DSM-
IV criteria for Alcohol and Nicotine Dependence. Nicotine Dependence diagnosis was 
confirmed by exceeding the nicotine-dependent cut off on the Fagerstrom Tolerance 
Questionnaire (Fagerstrom, 1978), (b) were unrelated Caucasians, (c) were not current 
polysubstance or illicit drug misusers (with the exception of greater than once per month 
marijuana misuse), (d) did not have any life-threatening alcohol-related medical 
complications, (e) were physically and mentally well enough to undertake a clinical 
interview, and (f) provided written informed consent to participate in the clinical interview 
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and to have blood drawn for DNA analysis. The mean age of these 84 subjects was 40 years 
(s.d. = 9.25 years, range = 22-63 years).  
 
2.2 Clinical Assessment 
Medical staff initially assessed all patients and a psychologist subsequently conducted the 
clinical interview. The interview included basic demographic information and assessed 
tobacco/alcohol consumption and severity of nicotine/alcohol dependence. The research 
protocol was approved by the Ethics Committee of the Royal Brisbane and Women’s 
Hospital and The University of Queensland. All patients provided informed written 
consent to participate in the study.  
 
2.2.1 Consumption: Nicotine 
Cigarettes smoked per day was assessed by the question: “On average, how many cigarettes 
do you smoke each day?” The clinician assisted the patient with quantification, for example 
to assess if there was a variation between weekday smoking and smoking at weekends. If 
the patient made his or her own cigarettes rather than smoked manufactured cigarettes, the 
clinician asked the patient to show them the typical thickness of the cigarette. A 
transformation to standard manufactured cigarettes was then made. Smoking frequency data 
were not examined separately as all smokers recruited reported smoking on a daily basis.  
 
Nicotine content of cigarettes in milligrams was assessed by asking the patient to report 
the “strength” of cigarettes smoked (e.g. 0.2 mg, 0.4mg, 0.8mg, 1.6mg of nicotine). If the 
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nicotine was assessed by content was unknown, the subject’s cigarette packet was 
examined or the brand noted so this could be established following the assessment. 
 
Nicotine dose consumed per week was determined by the composite variable consisting 
of Average Cigarettes Smoked per Day x mg content x 7. 
 
2.2.2 Consumption: Alcohol 
To fully describe alcohol consumption, both quantity and frequency measures were obtained 
(Rehm, 1998) using previously validated measures (Connor, Young, Williams & 
Ricciardelli, 2000; Connor, Gudgeon, Young, & Saunders, J.B., 2004; Gudgeon, Connor, 
Young & Saunders, 2005). The recommendations from the Skarpo conference (Dawson & 
Room, 2000) were followed, in that (i) Quantity of drinking measurement captured 
information in terms of quantity of drinks per occasion rather than quantity of drinks 
consumed per day and, (ii) Frequency of drinking should not be asked in an open-ended 
manner and should have a specified range in terms of times per week. 
 
Alcohol Quantity was assessed by the question: “On average, how many drinks do you 
consume on each daily drinking occasion?” Subjects were first shown pictures of a range of 
common alcohol servings (glasses, bottles, etc.), which included volume from colloquial 
Australian expressions (“pots”, “midis”, “schooners”, etc.). This was then transformed to a 
standardised measure (ie. grams of absolute alcohol). 
 
Drinking Frequency was the average number of drinking days per week (range= 0 to 7).  
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Ethanol Dose Per Week was calculated by multiplying Alcohol Quantity by Drinking 
Frequency. 
 
2.2.3 Dependence Severity 
Nicotine: The degree of physical dependence on nicotine was assessed by the Fagerstrom 
Tolerance Questionnaire (FTQ, Fagerstrom, 1978). FTQ scores correlate well with 
physiological measures of nicotine use such as cotinine level (Fagerstrom & Schneider, 
1989; Pomerleau, Pomerleau, Majchrazak, Kloska & Mulakuti, 1990). 
 
Alcohol: The Alcohol Dependence Scale (ADS, Skinner & Allen, 1982, Skinner & Horn, 
1984) questionnaire was used to quantify alcohol dependence severity. The ADS is a 
reliable and valid instrument for assessing level of dependence (Skinner & Allen, 1982). 
 
2.3 Genotyping 
A 10 ml blood sample was drawn from each patient. Genomic DNA was extracted 
employing standard techniques and used as a template for determination of TaqI A DRD2 
alleles by the polymerase chain reaction (Grandy, Zhang & Civelli 1993). The 
amplification of DNA was carried out using a Perkin Elmer GeneAmp 9600 
thermocycler. Approximately 500 ng of amplified DNA was digested with 5 units of TaqI 
restriction enzyme (New England Biolabs) at 65°C. The resulting products were 
separated by electrophoresis in a 2.5% agarose gel containing ethidium bromide and 
visualized under ultraviolet light. The A1/A2 genotype is revealed by three fragments: 
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310 bp, 180 bp and 130 bp; the A2/A2 genotype by two fragments: 180 bp and 130 bp; 
and the A1/A1genotype is shown by the uncleaved 310 bp fragment. All genotyping was 
carried out blind to the subjects’ results in the clinical assessment in that the DNA data 
were not available to the researchers until the clinical assessments were completed. A1+ 
allelic subjects were those that either had the A1/A1 or A1/A2 genotype; A1- allelic 
subjects had the A2/A2 genotype only.  
 
2.4 Statistics 
Analyses on the interval data were conducted by multivariate and univariate Analyses of 
Variance (ANOVA). Analyses on the nominal data were conducted by chi square statistic 
(Fisher’s Exact Test). All analyses were conducted with SPSS Version 11. A p value of # 
.05 was considered to be statistically significant. 
 
 
3. Results 
 
3.1 Genotypes  
Of the 84 smokers in this study, 30 had the A1+ allele (four A1/A1 and 26 A1/A2 
genotypes) and 54 had the A1- allele (A2/A2 genotype). A1 allelic frequency = 0.20 and 
A2 allelic frequency = 0.80. In the excluded sample of non-smokers, 5 subjects had the 
A1+ allele (one A1/A1 and four A1/A2 genotypes) and 17 had the A1- allele (A2/A2 
genotype). A1 allelic frequency = 0.14 and A2 allelic frequency = 0.86. There was no 
significant difference in allelic frequencies between smokers and the excluded non-
smokers (χ2 = 0.61, p = .44). 
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3.2 Sex and Age Variables 
To investigate possible variation in consumption on the basis of sex and age proportions 
between allelic groups, two chi-square analyses were undertaken. There was no 
significant difference in the proportion of males and females in either allelic group (χ2 = 
2.70, p= 0.13). Similarly, there was no significant difference in mean age (at assessment) 
between allelic groups. The mean age for A1+ allelic subjects was 39.9 years (s.d. = 10.6) 
and 40.0 years (s.d. = 8.5) for A1- allele subjects (F (1, 82) = 0.005, p = .94).  
 
3.3 Smoking and Drinking Variables by Allelic Group 
To investigate if there was an overall difference in allelic status between smoking and 
drinking variables, a MANOVA was conducted on the 84 smoking subjects. Composite 
variables (i.e. weekly mg nicotine consumption and weekly standard drinks consumed) 
were considered separately, as they possessed a high level of multicollinearity (Hair, et 
al., 1995). An overall allele effect trend was found (Hotelling's T2 = .858, F [6, 77] = 
2.12, p =.06). There was a significant difference between allelic groups within the 
composite smoking and drinking variables (Hotelling's T2 = .150, F [2, 81] = 6.08, p 
=.003), with the A1+ allelic participants reporting a higher consumption than their A1- 
allelic counterparts. Table 1 provides the effect size, means and standard deviations of the 
univariate analyses for all smoking and drinking variables.  
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_______________________________________ 
 
INSERT TABLE 1 HERE 
________________________________________ 
 
3.4 Smoking and Drinking Severity: Standard Score Composite by Allele Group 
To examine the relationship between allelic status and the combined effect of smoking 
and drinking, Total Nicotine Dose per Week and Ethanol Dose per Week per were 
initially transformed to standard (Z) scores. The range for Total Nicotine Dose per Week 
was -1.46 to 2.06 and -1.56 to 4.71 for Ethanol Dose per Week. The two standard scores 
were combined to form a composite nicotine/alcohol dose per week. ANOVA indicated 
that that the A1+ allelic group reported a significantly higher combined nicotine/alcohol 
dose (mean= .82, s.d. = 1.78) than the A1- allelic subjects (mean= -.37, s.d. = 1.37) (F (1, 
82) = 11.68, p = .001). 
 
To further examine the hypothesis that individuals carrying the A1+ allele are likely to 
consume higher substance doses of both nicotine and alcohol than subjects with the A1- 
allele, a median split procedure categorised the sample into low/high Nicotine Dose per 
Week and low/high Standard Drinks per Week. Subjects were then allocated to four 
categories a) Low Nicotine per Week/Low Alcohol per Week (n=23), b) Low Nicotine 
per Week/High Alcohol per Week (n= 15), c) High Nicotine per Week/Low Alcohol per 
Week (n=17), d) High Nicotine Per Week/High Alcohol per Week (n=29). To examine 
whether the A1 allele was a marker of severity in the current sample the three groups 
representing heavy use of either alcohol or nicotine or both (Groups b, c and d) were 
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combined to constitute a severe use sample and compared to the group that used both 
substances at below the median (Group a). Chi-square analysis indicated a significant 
difference in allelic status between the severe misuse sample and those using both 
cigarettes and alcohol below the median (χ2 = 4.63, p=.03).  
 
4. Discussion 
The current study reports the association of the A1 allele of the DRD2 with severity 
markers of substance misuse amongst problem drinkers who are also nicotine dependent. 
A1+ allelic participants were exposed to greater health risk via their combined 
consumption of a higher number of cigarettes and a higher dose of alcohol than their A1- 
allelic counterparts. Prior studies have shown independent associations of DRD2 allelic 
status with smoking and drinking, however the examination of combined risk has not 
previously been assessed. It is well-documented that individuals that are nicotine-
dependent have a greater risk of alcohol dependence severity (Daeppen et al., 2000). The 
carcinogenic risk (particularly of the oropharyngeal region and gastrointestinal tract) 
associated with the combination of heavy cigarette and alcohol use is enhanced. The A1 
allele is associated with a familial aggregation of smoking-related cancers in research 
where smoking behaviour was measured but the role of alcohol was not examined (Wu et 
al, 2000). 
 
These findings underscore the importance of establishing a comprehensive substance use 
history in association studies of the A1 allele of the DRD2. Given that the DRD2 A1 
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allele has also been associated with severe substance misuse across a range of substances 
(for a review see Young, Lawford, Nutting & Noble, 2004a), it is clearly not specific for 
alcohol or nicotine dependence. It is more likely to be associated with neurochemical 
reward mechanisms (Noble, 1996; Young, Lawford, Feeney, Ritchie & Noble, 2004b). 
Previous research has emphasised the importance of the DRD2 as a general risk factor for 
substance misuse (Noble, 2003; Lawford et al, 1997; Young et al, 2004a) rather than a 
marker of risk for a particular drug. As multiple substances influence dopaminergic 
activity, the examination of a single substance may result in an incomplete examination 
of allelic risk. This study indicates that amongst those seeking treatment for alcohol-
dependence who are also smokers, the subgroup using the most nicotine or alcohol, either 
alone or in combination, were more likely to carry the A1 allele.  
 
Given the common risk for both severe alcohol and/or nicotine misuse associated with the 
A1 allele, it is important that the potential to treat both disorders in a manner that heeds 
this risk is investigated. Those with alcohol-dependence have been shown to be receptive 
to undertake treatment of both disorders simultaneously (Saxon, McGuffin & Walker, 
1997). Previous pharmacogenetic treatment of alcohol dependence using bromocriptine, a 
dopamine agonist that acts at the D2 dopamine receptor has shown an interaction between 
DRD2 allelic and medication status with reductions in craving only being evident in the 
A1+ allelic group treated with bromocriptine (Lawford et. al., 1995). Recent research 
indicates that bromocriptine has promise in smoking cessation (Murphy et al., 2002) and 
future research should examine the addition of bromocriptine, or a similar D2 dopamine 
receptor agonist, to current treatments to facilitate the pharmacogenetic treatment of these 
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comorbid disorders.  
 
The current study is limited by the severe nature of the substance misuse problems within 
the sample and may not generalise to those who are not in treatment settings. 
Furthermore, the data are cross-sectional and are based on self report alone, without 
biochemical verification. In addition, examination of other aspects of smoking behaviour 
including craving, withdrawal severity and subjective reinforcement of nicotine may help 
to further elucidate the impact of the A1 allele.  
 
In summary, DRD2 A1+ allelic status is associated with increased misuse of alcohol and 
nicotine and the heavy comorbid misuse of both substances in an alcohol-dependent 
sample. The evidence supports the association of the A1 allele with severe substance 
misuse. This common genetic association of alcohol and nicotine dependence allows for 
the possibility of a targeted pharmacogenetic approach that may ameliorate both disorders 
simultaneously producing improved general health and decreased risk for associated 
upper digestive and respiratory tract disorders. 
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Table 1. Smoking and drinking parameters by DRD2 allelic status* 
 
 
 
* A1+ allele are individuals with the A1A1 or A1A2 genotype, A1- allele are individuals with the 
A2A2 genotype only. 
Measure A1+ Allele A1- Allele Effect Size 
 Mean S.D. Mean S.D. F P 
Smoking Indices 
 
      
Cigarettes per day 
 
36.2 16.8 27.5 14.3 6.34 .014 
Nicotine content (mg) 1.36 .41 1.17 .47 3.55 .063 
Fagerstrom Tolerance 
Questionnaire 
 
7.07 2.61 6.24 2.83 1.74 .191 
Drinking Indices 
 
      
Drinking Frequency (days per 
week) 
 
6.20 1.58 6.06 1.37 .19 .662 
Drinking Quantity per day (g) 
 
217 106 167 84 5.70 .019 
Alcohol Dependence Scale 
(ADS) 
 
33.76 9.34 29.94 8.89 3.44 .067 
Composite Variables 
 
      
Nicotine dose per week (mg) 
 
364 203 235 168 9.81 .002 
Ethanol dose per week (g) 
 
1366 768 1031 587 5.00 .028 
